The State of Weight-Loss Drugs
Motley Fool Money
Semaglutide Supply and Weight Loss Drug Innovations
This chapter covers the FDA's announcement on the end of the semaglutide shortage and its impact on major pharmaceutical companies like Eli Lilly and Novo Nordisk. It also examines the role of compounding pharmacies, the challenges faced by Hims and Hers, and the complexities surrounding the prescription and regulation of GLP-1 drugs, particularly regarding eating disorders. Furthermore, the chapter discusses the development of new weight loss medications, including Eli Lilly's orforglipron, and the implications of patent timelines and pricing strategies for access to these treatments.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
